Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$11.13 -7.9%	$10.23	$4.88 ▼ $19.58	$262.09M	N/A	27,509 shs	51,988 shs
FHTX Foghorn Therapeutics	$4.72 -0.6%	$4.25	$2.94 ▼ $10.25	$264.77M	3.04	143,157 shs	162,682 shs
LXRX Lexicon Pharmaceuticals	$0.75 +0.6%	$0.65	$0.28 ▼ $2.45	$269.49M	1	6.70 million shs	4.33 million shs
SBOT Stellar Biotechnologies	$10.90 +1.3%	$59,624.23	$0.75 ▼ $3.25	$58.10M	N/A	2.95 million shs	2.96 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	0.00%	+9.22%	+9.82%	+21.90%	+1,207,999,900.00%
FHTX Foghorn Therapeutics	0.00%	+4.63%	+14.73%	+17.28%	-9.18%
LXRX Lexicon Pharmaceuticals	0.00%	+7.14%	+30.79%	+105.26%	-57.40%
SBOT Stellar Biotechnologies	+1.30%	-14.58%	+3.81%	+57.29%	+431.71%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	1.7076 of 5 stars	3.6	2.0	0.0	0.0	0.0	1.7	0.6
LXRX Lexicon Pharmaceuticals	2.6454 of 5 stars	3.2	4.0	0.0	0.0	1.4	2.5	0.6
SBOT Stellar Biotechnologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AARD Aardvark Therapeutics	3.00	Buy	$31.25	180.77% Upside
FHTX Foghorn Therapeutics	3.13	Buy	$12.13	156.89% Upside
LXRX Lexicon Pharmaceuticals	2.40	Hold	$3.67	388.89% Upside
SBOT Stellar Biotechnologies	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SBOT, FHTX, LXRX, and AARD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	AARD Aardvark Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$21.00 ➝ $20.00
5/15/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
5/14/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/30/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
4/30/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/23/2025	FHTX Foghorn Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/23/2025	FHTX Foghorn Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Mkt Outperform	$9.00
4/23/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$9.00
4/1/2025	AARD Aardvark Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$21.00 ➝ $21.00
4/1/2025	AARD Aardvark Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$50.00 ➝ $50.00
3/28/2025	LXRX Lexicon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	$22.60M	11.64	N/A	N/A	($0.82) per share	-5.76
LXRX Lexicon Pharmaceuticals	$31.08M	8.72	N/A	N/A	$0.40 per share	1.88
SBOT Stellar Biotechnologies	$210K	276.65	N/A	N/A	$2.12 per share	5.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AARD Aardvark Therapeutics	-$20.59M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	-$86.62M	-$1.36	N/A	N/A	N/A	-342.23%	N/A	-27.28%	8/6/2025 (Estimated)
LXRX Lexicon Pharmaceuticals	-$200.40M	-$0.51	N/A	N/A	N/A	-568.04%	-103.16%	-54.95%	7/30/2025 (Estimated)
SBOT Stellar Biotechnologies	-$5.03M	-$1.76	N/A	N/A	N/A	-1,782.64%	-51.12%	-48.37%	N/A

Latest SBOT, FHTX, LXRX, and AARD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	N/A	AARD Aardvark Therapeutics	-$0.70	-$0.71	-$0.01	-$0.71	N/A	N/A
5/14/2025	Q1 2025	FHTX Foghorn Therapeutics	-$0.30	-$0.30	N/A	-$0.30	$4.96 million	$5.95 million
5/13/2025	Q1 2025	LXRX Lexicon Pharmaceuticals	-$0.10	-$0.07	+$0.03	-$0.07	$1.26 million	$1.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SBOT Stellar Biotechnologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AARD Aardvark Therapeutics	N/A	25.86	25.86
FHTX Foghorn Therapeutics	N/A	3.16	3.16
LXRX Lexicon Pharmaceuticals	0.48	2.22	2.22
SBOT Stellar Biotechnologies	N/A	9.24	8.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AARD Aardvark Therapeutics	N/A
FHTX Foghorn Therapeutics	61.55%
LXRX Lexicon Pharmaceuticals	74.70%
SBOT Stellar Biotechnologies	1.69%

Insider Ownership

Company	Insider Ownership
AARD Aardvark Therapeutics	N/A
FHTX Foghorn Therapeutics	7.58%
LXRX Lexicon Pharmaceuticals	13.90%
SBOT Stellar Biotechnologies	7.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AARD Aardvark Therapeutics	18	21.70 million	N/A	N/A
FHTX Foghorn Therapeutics	120	55.74 million	51.52 million	Optionable
LXRX Lexicon Pharmaceuticals	140	361.49 million	311.25 million	Optionable
SBOT Stellar Biotechnologies	25	5.33 million	N/A	Not Optionable

SBOT, FHTX, LXRX, and AARD Headlines

Recent News About These Companies

Serve Robotics ties up with Alphabet's unit for drone deliveries, launching pilot in Texas

October 1, 2024 | reuters.com

Are robots the future of food delivery? Serve Robotics thinks so

May 5, 2024 | finance.yahoo.com

Uber, Nvidia-backed Serve Robotics hits public markets with $40M splash

April 18, 2024 | techcrunch.com

Stellar Blade Demo Walkthrough

April 17, 2024 | ign.com

Been Stellar

March 11, 2024 | nme.com

The real reason Terry Biviano signed up to be a Housewife

October 31, 2023 | dailytelegraph.com.au

Zach Wilson’s stellar day at Jets camp includes long touchdown throw

July 30, 2023 | nypost.com

Caterpillar's Stellar Move To Attract High-Quality Employees

June 7, 2023 | forbes.com

Audio-Technica AT2020USB-X review - Simple for stellar streaming

May 10, 2023 | techradar.com

Ravens Expect to Bring Back Stellar Offensive Line

February 26, 2023 | si.com

2023 NFL combine: Detroit Lions could re-invest in their stellar offensive line

February 26, 2023 | mlive.com

Stellar Bancorp, Inc. Declares Quarterly Dividend

February 26, 2023 | benzinga.com

MSU-Mankato rallies past Dragons women with stellar 3rd-quarter performance

February 5, 2023 | inforum.com

O's closer Felix Bautista goes on DL ending stellar rookie year

October 5, 2022 | cbsnews.com

Daniel Ryan one of the stellar cast members of new gripping BBC thriller Crossfire partly set in Leicester

September 24, 2022 | leicestermercury.co.uk

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBOT, FHTX, LXRX, and AARD Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

$11.13 -0.95 (-7.86%)

As of 04:00 PM Eastern

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Foghorn Therapeutics NASDAQ:FHTX

$4.72 -0.03 (-0.63%)

Closing price 04:00 PM Eastern

Extended Trading

$4.70 -0.01 (-0.32%)

As of 04:11 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Lexicon Pharmaceuticals NASDAQ:LXRX

$0.75 +0.00 (+0.60%)

Closing price 04:00 PM Eastern

Extended Trading

$0.74 -0.01 (-1.07%)

As of 07:55 PM Eastern

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Stellar Biotechnologies NASDAQ:SBOT

Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia. The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market. It provides its KLH protein under the Stellar KLH brand. The company's products include Stellar KLH protein in various grades, formulations, custom configurations, and fill finishes for drug development and research applications, as well as KLH-based in vitro diagnostic kits for research and preclinical use. Its customers and partners comprise biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time